Clinical Trials in Los Angeles

Obexelimab — NCT06559163: A Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of obexelimab in systemic lupus erythematosus.

Cenerimod — NCT05648500: A Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating cenerimod in adults with moderate-to-severe systemic lupus erythematosus receiving background therapy.

ELECTRA — NCT05386108: An open-label Phase 1b/2 study of elacestrant with abemaciclib in women and men with ER-positive, HER2-negative breast cancer and brain metastases.

OP-1250 — NCT06016738: A Phase 3 randomized study comparing OP-1250 monotherapy with standard-of-care treatment for ER-positive, HER2-negative advanced or metastatic breast cancer after endocrine therapy and a CDK4/6 inhibitor.

(Z)-endoxifen — NCT05607004: A Phase 2 study of (Z)-endoxifen-based neoadjuvant treatment in premenopausal women with ER-positive, HER2-negative breast cancer.

DB-1305 — NCT05438329: A Phase 1/2a, multicenter, first-in-human study evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity in advanced or metastatic solid tumors.

INBRX-106 — NCT04198766: A Phase 1/2 study evaluating INBRX-106 alone and with pembrolizumab in locally advanced or metastatic solid tumors.

ZEN003694 — NCT04986423: A randomized Phase 2b study of ZEN003694 with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer.

EIK1001 — NCT06246110: A Phase 2 study of EIK1001 with pembrolizumab and chemotherapy for Stage IV non-small cell lung cancer.

Trastuzumab deruxtecan study — NCT06899126: A Phase 3 study comparing trastuzumab deruxtecan plus pembrolizumab with platinum-based chemotherapy plus pembrolizumab as first-line treatment for eligible HER2-overexpressing, PD-L1-low non-squamous NSCLC.

Sotorasib combination study — NCT06252649: A Phase 3 study of sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb in previously untreated metastatic colorectal cancer with a KRAS G12C mutation.

Navtemadlin — NCT06479135: A Phase 3 study evaluating navtemadlin plus ruxolitinib versus placebo plus ruxolitinib in myelofibrosis with a suboptimal response to ruxolitinib.

BNT113 — NCT04534205: A Phase 2/3 study of first-line therapy for unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head and neck squamous cell carcinoma.

Cancer biomarker observational study: An observational study evaluating tumor biomarker and molecular characteristics in blood samples from people with cancer.